Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in recurrent/persistent clear cell carcinoma of the ovary, fallopian tube, peritoneum, and endometrium
NCT02059265Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2014
- Primary completion
- Feb 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in ovarian clear cell carcinoma (OCCC), fallopian tube clear cell carcinoma (FTCCC), primary peritoneal clear cell carcinoma (PPCCC) and 1 more, sponsored by National Cancer Institute. Primary endpoint: Objective Tumor Response Rate at 12 months. Started Feb 2014; status: terminated.
02
Drugs
dasatinib
03
Conditions
ovarian clear cell carcinoma (OCCC)fallopian tube clear cell carcinoma (FTCCC)primary peritoneal clear cell carcinoma (PPCCC)endometrial clear cell carcinoma (ECC)
Beyond the preview
Go deeper on NCT02059265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059265.